Amgen Inc. (NASDAQ:AMGN) Stock Holdings Lifted by Appleton Partners Inc. MA

Appleton Partners Inc. MA raised its stake in Amgen Inc. (NASDAQ:AMGN) by 1.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 20,313 shares of the medical research company’s stock after acquiring an additional 279 shares during the period. Appleton Partners Inc. MA’s holdings in Amgen were worth $5,775,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AMGN. Kapitalo Investimentos Ltda raised its stake in Amgen by 88.9% during the 4th quarter. Kapitalo Investimentos Ltda now owns 1,921 shares of the medical research company’s stock valued at $553,000 after purchasing an additional 904 shares during the period. Nomura Holdings Inc. acquired a new stake in Amgen during the 4th quarter valued at $3,104,000. HighPoint Advisor Group LLC acquired a new stake in Amgen during the 4th quarter valued at $3,068,000. Napatree Capital LLC acquired a new stake in Amgen during the 4th quarter valued at $358,000. Finally, Livelsberger Financial Advisory acquired a new stake in Amgen during the 4th quarter valued at $50,000. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on AMGN. UBS Group boosted their target price on shares of Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. BMO Capital Markets upped their price target on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Mizuho upped their price target on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Royal Bank of Canada upped their price target on shares of Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $305.85.

Amgen Stock Performance

AMGN stock traded up $1.21 during mid-day trading on Tuesday, reaching $304.49. 427,927 shares of the stock traded hands, compared to its average volume of 2,729,426. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 52 week low of $218.44 and a 52 week high of $329.72. The business has a 50-day moving average of $293.45 and a two-hundred day moving average of $289.82. The firm has a market capitalization of $163.34 billion, a PE ratio of 43.65, a P/E/G ratio of 2.70 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. During the same period in the prior year, the company earned $3.98 earnings per share. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. As a group, equities analysts predict that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.